http://archderm.jamanetwork.com/ en-us Wed, 14 Nov 2012 00:00:00 GMT Tue, 01 Jan 2013 00:44:35 GMT Silverchair editor@archderm.jamanetwork.com webmaster@archderm.jamanetwork.com http://archderm.jamanetwork.com/article.aspx?articleID=421347 Sat, 01 May 2010 00:00:00 GMT Keenan BP, Abuav R. <span class="paragraphSection">Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is used in the treatment of several cancers, macular degeneration, and proliferative diabetic retinopathy as a means of limiting angiogenesis, a hallmark feature of these diseases. Nonspecific skin eruption has been reported in some patients receiving bevacizumab, and recently, bevacizumab-associated acneiform eruption was reported in the treatment of colon cancer (systemic administration) and macular degeneration (intravitreal administration). The eruption in these patients was strikingly similar to that characterized in patients treated with epidermal growth factor receptor (EGFR) inhibitors. We report a case of bevacizumab-induced acneiform eruption in a patient with glioblastoma multiforme.</span> 146 5 577 577 10.1001/archdermatol.2010.68 http://archderm.jamanetwork.com/article.aspx?articleID=421347